ALBIGER, NORA MARIA ELVIRA
 Distribuzione geografica
Continente #
NA - Nord America 3.403
EU - Europa 406
AS - Asia 377
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 4.190
Nazione #
US - Stati Uniti d'America 3.397
CN - Cina 214
SG - Singapore 81
DE - Germania 74
IT - Italia 74
SE - Svezia 65
VN - Vietnam 64
FI - Finlandia 61
GB - Regno Unito 50
UA - Ucraina 39
FR - Francia 24
IN - India 9
IE - Irlanda 8
BZ - Belize 5
NL - Olanda 4
PL - Polonia 4
JP - Giappone 3
TR - Turchia 2
AM - Armenia 1
AU - Australia 1
BE - Belgio 1
CA - Canada 1
CO - Colombia 1
EU - Europa 1
HK - Hong Kong 1
HU - Ungheria 1
IR - Iran 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 4.190
Città #
Fairfield 571
Woodbridge 347
Chandler 334
Ann Arbor 322
Houston 251
Ashburn 246
Seattle 210
Cambridge 207
Wilmington 186
Jacksonville 168
Beijing 81
Princeton 68
Dong Ket 64
Singapore 62
San Diego 50
Des Moines 38
Medford 28
Padova 28
Helsinki 26
Nanjing 26
Boardman 24
Frankfurt am Main 23
Roxbury 20
Nanchang 10
Santa Clara 9
Dublin 8
Jiaxing 7
London 7
Los Angeles 7
Shenyang 7
Falls Church 6
Florence 6
Jinan 6
New York 6
Redwood City 6
Zhengzhou 6
Belize City 5
Hebei 5
Hefei 5
Renton 5
San Jose 5
Tianjin 5
Borås 4
Columbus 4
Indiana 4
Kunming 4
Norwalk 4
Changsha 3
Dearborn 3
Kharkiv 3
Ogden 3
Shanghai 3
Washington 3
Agrigento 2
Albuquerque 2
Auburn Hills 2
Catania 2
Fuzhou 2
Istanbul 2
Lanzhou 2
Las Vegas 2
Milan 2
Nürnberg 2
Paris 2
Piove Di Sacco 2
Rockville 2
Rome 2
Urbino 2
Vicenza 2
Wroclaw 2
Acton 1
Atlanta 1
Augusta 1
Buffalo 1
Böblingen 1
Canberra 1
Carmignano Di Brenta 1
Charlotte 1
Chicago 1
Chiswick 1
Chongqing 1
Christchurch 1
Groningen 1
Guangzhou 1
Haikou 1
Hangzhou 1
Hounslow 1
Islington 1
Kiev 1
Kilburn 1
Latsch 1
Leawood 1
Liège 1
Magdeburg 1
Medellín 1
Miami 1
Mumbai 1
New Bedfont 1
Newark 1
Ningbo 1
Totale 3.603
Nome #
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 162
Diagnosis and complications of Cushing's disease: gender-related differences. 151
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor 134
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up 134
Screening tests for cushing's syndrome: Urinary free cortisol role measured by LC-MS/MS 129
The Role of Unilateral Adrenalectomy in ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH). 126
An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: A single-centre experience 123
A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion? 121
Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. 119
Early recognition of aggressive pituitary adenomas: a single-centre experience 117
Metyrapone treatment in Cushing’s syndrome: a real-life study 115
Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? 111
Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate 109
Adrenal nodules in patients with Cushing's disease: prevalence, clinical significance and follow-up. 103
Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency 103
Different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia 102
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 101
Second-line tests in the differential diagnosis of ACTH-dependent Cushing’s syndrome 100
Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study 100
A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype 99
Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma 97
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study 96
Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. 95
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 93
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives GH-promoter activity in GH3 cells. 92
Therapeutic strategies for Cushing's syndrome: An update 90
Predicting late recurrence in surgically-treated patients with Cushing's disease. 87
The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging 86
Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. 86
Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus 84
Adrenal morpho-functional alterations in patients with acromegaly. 82
Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules 81
Microsatellite (GT)(n) is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome. 79
Effect of short term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerosis markers in hypopituitary patients with growth hormone deficiency. 79
Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. 78
The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas 76
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. 69
Cyclic Cushing's syndrome: an overview. 65
Haplotypes of Von Willebrand factor promoter predict thrombotic risk in Cushing's syndrome 63
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. 62
Aterosclerosi extra coronaria nella sindrome di Cushing 59
Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. 54
Utilità  dell'uso dei test (DDAVP, CRH e 8 MG DEX OVERNIGHT) nell'indicazione chirurgica e nell'outcome della malattia di Cushing 51
Sindrome di Cushing e rischio cardiovascolare 48
The role of the size in thyroid cancer risk stratification 48
Corticotropin-releasing hormone test predicts the outcome of unilateral adrenalectomy in primary bilateral macronodular adrenal hyperplasia 6
Totale 4.265
Categoria #
all - tutte 15.332
article - articoli 14.884
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.216


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020849 0 0 17 112 98 70 101 109 110 101 77 54
2020/2021612 37 51 30 53 15 27 13 50 79 93 66 98
2021/2022685 14 73 82 52 63 48 18 87 28 15 63 142
2022/2023583 125 89 6 89 78 71 1 36 54 3 26 5
2023/2024267 5 39 33 14 31 30 36 12 5 7 26 29
2024/2025120 5 50 65 0 0 0 0 0 0 0 0 0
Totale 4.265